Fig. 1
High expression of TRIP13 is associated with poor GBM patient prognosis. a Immunohistochemical staining analysis showed the expression of TRIP13 in 8 paired normal brain tissues and 12 paired GBM tissue samples. b Immunohistochemistry analyses is shown for TRIP13 expression levels in 8 paired normal brain tissue samples and 12 paired GBM tissue samples, P < 0.001. c Kaplan–Meier analysis of progression-free survival data from the Tumour Glioma Kawaguichi-50 database with the log-rank test P-values indicated. d, e Quantitative PCR assays and western blot assays were performed to detect the expression of TRIP13 in normal astrocytes (SVGP12) and GBM cell lines (A172, LN229, U118 and U87MG)
